Cipla gets EIR from USFDA for Kurkumbh facility

| Updated on June 10, 2019 Published on June 10, 2019

Pharma major Cipla on Monday said it has received the establishment inspection report (EIR) from the US health regulator after inspection of the Kurkumbh facility in Maharashtra. The Kurkumbh manufacturing facility was inspected by the United States Food and Drug Administration (USFDA) from March 11 to March 20, 2019, Cipla said. The company has received the EIR indicating closure of inspection, it added. Shares of Cipla gained 0.75 per cent at ₹553.70 on the BSE.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on June 10, 2019
This article is closed for comments.
Please Email the Editor